Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05225610
Other study ID # IRC13412/02/9
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 19, 2022
Est. completion date September 10, 2022

Study information

Verified date October 2022
Source Tanta University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

No previous study has cited the use of the Valsalva manoeuvre for the reduction of pain on propofol injection in comparison with dexmedetomidine injection. Therefore, investigators plan a study to evaluate the analgesic efficacy of the Valsalva manoeuvre in alleviating pain during propofol injection as compared to dexmedetomidine injection.


Description:

Propofol is a commonly used anaesthetic for inducing general anaesthesia. Pain on propofol injection is distressing and is one of the limitations of its use. Propofol is a phenol compound, which irritates nerve endings on the venous endothelium to produce immediate pain, whereas delayed pain is mediated by the release of bradykinin. Bradykinin causes vasodilation and increases venous permeability, thereby facilitating contact of the aqueous phase of propofol with nerve endings. Delayed pain occurs 10-20 seconds after injection. Various methods have been tried so far to reduce pain on propofol injection. A commonly used technique is lignocaine either as pre-treatment or mixed with propofol. Other methods include the use of butorphanol, ondansetron, metoclopramide, opioid, or thiopentone. Propofol injection into a large vein, pre-injection cooling, or warming of propofol have also been investigated. The Valsalva manoeuvre is a physiological technique, used in the reduction of pain associated with several procedures. The Valsalva manoeuvre alleviates both the somatic and psychological aspects of painful procedures. Dexmedetomidine is an alpha-2 adrenoceptor agonist that has analgesic and sedative properties, it has been evaluated for reducing the incidence and intensity of propofol-induced pain, but reported results are inconsistent. in this study, investigators will study the effect of Valsalva manoeuvre as compared with dexmedetomidine injection in reducing the pain associated with propofol injection in upper gastrointestinal endoscopies.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date September 10, 2022
Est. primary completion date April 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: 1. Adult patients aged 30-60 years old. 2. American Society of Anesthesiologist physical status(ASA) Grade I and II. 3. Upper gastrointestinal Endoscopies. Exclusion Criteria: 1. Patients with mental illness, restlessness. 2. Cardio-respiratory disease. 3. Chronic pain disorder. 4. Use of preoperative analgesic medication. 5. History of propofol allergy. 6. History of drug abuse. 7. Inability to perform the Valsalva manoeuvre. -

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Valsalva Manoeuvre
Blowing into rubber tubing connected to a sphygmomanometer and raising the mercury column to 30 mmHg for at least 20 seconds
Drug:
Dexmedetomidine Injection [Precedex]
The study drugs will be kept at room temperature, preservative-free and will be prepared by an independent anaesthetist into 5 ml of total volume with the addition of 0.9 % normal saline. Tourniquet will be left inflated for 1 minute. Dexmedetomidine mixture and saline will be injected over 5 seconds. After the injection of the drugs, the tourniquet will be released
normal Saline
5 ml saline will be administered.

Locations

Country Name City State
Saudi Arabia Sharurah Armed Forces Hospital Sharurah Najran

Sponsors (1)

Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain Assessment using a ruler as the visual analogue scale(VAS), The VAS score ranged from 0-10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Patients will be instructed to mark a point on the VAS ruler that represented the intensity of pain. The pain score was determined by measuring the distance in mm between 0 (no pain) and the mark will be indicated by the patient on the ruler. 20 seconds after propofol injection.
Secondary Withdrawal response score withdrawal response will be assessed using standard questions including comfort during injection, verbal response, and behavioural signs (facial grimacing, arm withdrawal, or tears). the withdrawal response scoring will be graded on a 4-point scale: 0 = no pain, 1 = mild pain (pain reported only in response to questioning without any behavioural signs), 2 = moderate pain (pain reported in response to questioning and accompanied by behavioural signs or pain reported spontaneously without questioning), and 3 = severe pain (strong vocal response or response accompanied by facial grimacing, arm withdrawal, or tears). 20 seconds after propofol injection
Secondary Heart Rate(HR) beat / minute the heart rate (HR) will be recorded before the Valsalva manoeuvre, at 1 minute, at 2 minutes after the manoeuvre, following propofol injection, and 5 minutes later on 10 minutes
Secondary Propofol injection site reaction the propofol injection site will be checked for signs of inflammation including oedema, pain, wheal, and flare 24 hour
Secondary Non-invasive blood pressure(NIBP) mmHg Non-invasive blood pressure(NIBP) will be recorded before the Valsalva manoeuvre, at 1 minute, 2 minutes after the manoeuvre, following propofol injection, and 5 minutes later on. 10 minutes.
See also
  Status Clinical Trial Phase
Terminated NCT04356352 - Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain Phase 2/Phase 3
Not yet recruiting NCT05109000 - Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline Phase 4
Completed NCT04582032 - Effects of Cyclooxygenase (COX) 1-2 Inhibitors on Prevention of Rocuronium Injection Pain N/A
Completed NCT02524743 - The Prevention of Pain Associated With Rocuronium Injection Phase 4
Completed NCT04673500 - Assessment of Pain on Propofol Injection. N/A
Recruiting NCT05378113 - Ondansetron as a Strategy for Reducing Propofol Injection Pain in Pediatrics: a Randomized Controlled Trial Phase 2
Completed NCT01824758 - Effect of Esmolol on Pain Due to Rocuronium Phase 4
Completed NCT04555980 - Warm Patch Decrease Propofol Injection Pain N/A
Completed NCT04436666 - Virtual Reality, Ice Application and Self-injection and Self-test Fair, Pain and State Anxiety N/A
Recruiting NCT03420560 - A Warmer Temperature Decrease Propofol Injection Pain N/A
Recruiting NCT05221333 - Sorrel 25R Injector - Sorrel Clinical Study Protocol N/A
Recruiting NCT05269823 - Topical Ice-therapy for Intravitreal Injections N/A